Aprea Therapeutics Inc (APRE) has released an update to notify the public and investors about an entry into a material definitive agreement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aprea Therapeutics, Inc. has entered into a sales agreement with H.C. Wainwright & Co., LLC, allowing for the at-the-market offering of its common stock up to $1.0 million. The sales are contingent on a Registration Statement filed with the SEC, with proceeds intended for general corporate uses such as preclinical and clinical trials. The agreement permits termination by either party and obligates the company to pay a 3% commission on sales proceeds to HCW, along with providing customary indemnification rights.
For further insights into APRE stock, check out TipRanks’ Stock Analysis page.